- Home
- CHRS vs SDST Comparison
CHRS vs SDST Comparison
Compare CHRS & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SDST
- Stock Information
- Founded
- CHRS 2010
- SDST 2022
- Country
- CHRS United States
- SDST United States
- Employees
- CHRS 235
- SDST N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SDST Blank Checks
- Sector
- CHRS Health Care
- SDST Finance
- Exchange
- CHRS Nasdaq
- SDST Nasdaq
- Market Cap
- CHRS 134.4M
- SDST 176.9M
- IPO Year
- CHRS 2014
- SDST N/A
- Fundamental
- Price
- CHRS $1.22
- SDST $0.79
- Analyst Decision
- CHRS Strong Buy
- SDST Strong Buy
- Analyst Count
- CHRS 4
- SDST 1
- Target Price
- CHRS $5.38
- SDST $13.00
- AVG Volume (30 Days)
- CHRS 2.4M
- SDST 1.6M
- Earning Date
- CHRS 03-12-2025
- SDST 02-15-2025
- Dividend Yield
- CHRS N/A
- SDST N/A
- EPS Growth
- CHRS N/A
- SDST N/A
- EPS
- CHRS N/A
- SDST N/A
- Revenue
- CHRS $304,340,000.00
- SDST N/A
- Revenue This Year
- CHRS $2.47
- SDST N/A
- Revenue Next Year
- CHRS N/A
- SDST N/A
- P/E Ratio
- CHRS N/A
- SDST N/A
- Revenue Growth
- CHRS 44.19
- SDST N/A
- 52 Week Low
- CHRS $0.66
- SDST $0.76
- 52 Week High
- CHRS $2.87
- SDST $28.38
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- SDST N/A
- Support Level
- CHRS $1.03
- SDST N/A
- Resistance Level
- CHRS $1.23
- SDST N/A
- Average True Range (ATR)
- CHRS 0.13
- SDST 0.00
- MACD
- CHRS -0.02
- SDST 0.00
- Stochastic Oscillator
- CHRS 38.89
- SDST 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is a development stage manufacturer of battery-grade lithium products deigned to supply the EV industry and helping to secure America's leadership in the energy transition. They enjoy a diversified supply of lithium from American brine sources.